Determination of miglitol in human plasma by HPLC-MS/ESI

Chinese Pharmaceutical Journal

Volumn 40, Issue 1, 2005, Pages 51-53

  Wang, Feng ^a   Zhou, Jin ^b   Xiang, Da Xiong ^a   Xiao, Yi Wen ^a   Yuan, Hai Yan ^a   Xu, Ping ^a   Zhou, Zhi Ling ^a   Li, Huan De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

HPLC MS ESI; Miglitol; Pharmacokinetics

Indexed keywords

ACETONITRILE; BODY FLUIDS; CORRELATION METHODS; DEPOSITION; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; MASS SPECTROMETRY; PHARMACOKINETICS; PHOSPHORIC ACID;

ELECTROSPRAY IONIZATION (ESI); HUMAN PLASMA; MIGLITOL; SELECTION ION RECORDING (SIR) MODE;

DRUG PRODUCTS;

ACETONITRILE; METHANOL; MIGLITOL; PHOSPHORIC ACID;

AREA UNDER THE CURVE; ARTICLE; CORRELATION COEFFICIENT; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN;

EID: 14744280031     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Segal P, Feig PU, Schemthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenolamide in patients with NIDDM inadequately controlled by diet alone[J]. Diabetes Care, 1997,20,5: 687.
2. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients[J]. Diabetes Care, 1996,19(6):559.